UY33802A - Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja - Google Patents

Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja

Info

Publication number
UY33802A
UY33802A UY0001033802A UY33802A UY33802A UY 33802 A UY33802 A UY 33802A UY 0001033802 A UY0001033802 A UY 0001033802A UY 33802 A UY33802 A UY 33802A UY 33802 A UY33802 A UY 33802A
Authority
UY
Uruguay
Prior art keywords
immunogenic compositions
ionic strength
low ionic
antigen related
antigen
Prior art date
Application number
UY0001033802A
Other languages
English (en)
Inventor
Dominique Ingrid Lemoine
Stephane Andre Georges Godart
Laanan Amina
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of UY33802A publication Critical patent/UY33802A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan composiciones inmunógenas que comprenden un antígeno relacionado con M72, en las que la conductividad de la composición es de 13 mS/cm o menor, o la concentración de sales de la composición es de 130 mM o menor, y su uso en medicina.
UY0001033802A 2010-12-14 2011-12-14 Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja UY33802A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42272310P 2010-12-14 2010-12-14

Publications (1)

Publication Number Publication Date
UY33802A true UY33802A (es) 2012-07-31

Family

ID=45346501

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033802A UY33802A (es) 2010-12-14 2011-12-14 Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja

Country Status (32)

Country Link
US (5) US9730992B2 (es)
EP (4) EP2651437B1 (es)
JP (2) JP5951633B2 (es)
KR (3) KR101951894B1 (es)
CN (4) CN106822883A (es)
AR (1) AR084285A1 (es)
AU (2) AU2011343368C1 (es)
BR (2) BR112013014599A2 (es)
CA (2) CA2819297A1 (es)
CO (2) CO6751288A2 (es)
CY (1) CY1122187T1 (es)
DK (3) DK3023106T3 (es)
EA (2) EA027504B1 (es)
ES (3) ES2748651T3 (es)
HR (3) HRP20160362T1 (es)
HU (3) HUE028452T2 (es)
IL (2) IL226450A0 (es)
LT (1) LT3023106T (es)
ME (1) ME02380B (es)
MX (2) MX344706B (es)
MY (1) MY161412A (es)
PL (3) PL2651436T3 (es)
PT (2) PT2651436E (es)
RS (1) RS54687B1 (es)
SG (2) SG190731A1 (es)
SI (3) SI2651436T1 (es)
SM (1) SMT201600118B (es)
TW (1) TW201305192A (es)
UA (2) UA110118C2 (es)
UY (1) UY33802A (es)
WO (2) WO2012080370A1 (es)
ZA (2) ZA201304015B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150036658A (ko) 2005-04-29 2015-04-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
KR101951894B1 (ko) 2010-12-14 2019-02-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 미코박테리움 항원성 조성물
PL2661253T3 (pl) * 2011-01-04 2017-08-31 Archivel Farma, Sl Preparat liposomowy odpowiedni do leczenia lub zapobiegania gruźlicy
PL2802345T3 (pl) 2012-01-12 2018-08-31 Archivel Farma, S.L. Szczepionka mtb-c przeciw reakcjom alergicznym
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201522068D0 (en) 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) * 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
KR20210038919A (ko) 2018-07-31 2021-04-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 항원 정제 방법
EP3886901A1 (en) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2021048081A1 (en) 2019-09-09 2021-03-18 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
MX2022006054A (es) 2019-11-22 2022-06-24 Glaxosmithkline Biologicals Sa Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.
CA3181627A1 (en) 2020-05-05 2021-11-11 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
MX2023006769A (es) 2020-12-09 2023-08-18 Glaxosmithkline Biologicals Sa Modificacion de saponinas.
CN114034860A (zh) * 2021-11-01 2022-02-11 宁夏大学 一种结核分枝杆菌mtb39a蛋白抗体间接elisa检测方法及其试剂盒
WO2023242187A1 (en) 2022-06-15 2023-12-21 Glaxosmithkline Biologicals Sa Enzymatic modification of saponins
CN116120411B (zh) * 2022-12-07 2024-04-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
BR9610262B1 (pt) 1995-09-01 2013-11-26 Compostos e métodos para a imunoterapia e diagnose de tuberculose.
MX9801687A (es) 1995-09-01 1998-11-29 Corixa Corp Compuestos y metodos para el diagnostico de tuberculosis.
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9619613D0 (en) 1996-09-19 1996-10-30 Breed Automotive Tech An inflatable restraint for a vehicle
EP0859366A1 (en) 1997-02-12 1998-08-19 STMicroelectronics S.r.l. Associative memory device with optimized occupation, particularly for the recognition of words
DK0973546T3 (da) * 1997-04-08 2004-06-28 Merck & Co Inc Stabiliserede formuleringer med human papillomavirus
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
NZ507378A (en) 1998-04-07 2002-12-20 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and their uses
TR200002930T2 (tr) * 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
AU779978B2 (en) * 1999-10-07 2005-02-24 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
ES2333579T3 (es) 2000-06-20 2010-02-24 Corixa Corporation Proteinas de fusion de mycobacterium tuberculosis.
EA006313B1 (ru) 2000-06-29 2005-10-27 Глаксосмитклайн Байолоджикалс С.А. Поливалентные иммуногенные композиции и способы их применения
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
KR20150036658A (ko) * 2005-04-29 2015-04-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
WO2008140478A2 (en) * 2006-11-01 2008-11-20 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
EA018201B1 (ru) 2007-05-24 2013-06-28 Глаксосмитклайн Байолоджикалс С.А. Лиофилизированная антигенная композиция
CN101969971A (zh) * 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
KR100955470B1 (ko) * 2008-01-09 2010-04-30 대한민국(관리부서 질병관리본부장) 탄저 방어 항원의 제조 방법
US8409901B2 (en) 2008-03-11 2013-04-02 The Royal Institution For The Advancement Of Learning/Mcgill University Low temperature wafer level processing for MEMS devices
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
IT1400834B1 (it) 2010-07-07 2013-07-02 Aero Sekur S P A Metodo e sistema per l'atterraggio di emergenza di un veicolo, come un elicottero o simili.
KR101951894B1 (ko) 2010-12-14 2019-02-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 미코박테리움 항원성 조성물
GB201400819D0 (en) 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition

Also Published As

Publication number Publication date
HUE027932T2 (en) 2016-11-28
PT2651436E (pt) 2016-06-08
CA2819298A1 (en) 2012-06-21
EA201390630A1 (ru) 2013-12-30
ME02380B (me) 2016-06-20
US10441648B2 (en) 2019-10-15
US9352030B2 (en) 2016-05-31
UA110118C2 (uk) 2015-11-25
CN103249431A (zh) 2013-08-14
EA201390631A1 (ru) 2014-11-28
AR084285A1 (es) 2013-05-08
CN106822882A (zh) 2017-06-13
WO2012080369A1 (en) 2012-06-21
HRP20160606T1 (hr) 2016-07-01
DK3023106T3 (da) 2019-09-30
SMT201600118B (it) 2016-07-01
US20160220656A1 (en) 2016-08-04
IL226448A (en) 2017-09-28
EP3023106A1 (en) 2016-05-25
PT3023106T (pt) 2019-11-04
CO6751288A2 (es) 2013-09-16
EP3593813A1 (en) 2020-01-15
MX2013006818A (es) 2013-08-26
US20190183998A1 (en) 2019-06-20
BR112013014598A2 (pt) 2017-09-19
PL3023106T3 (pl) 2019-12-31
AU2011343368C1 (en) 2015-12-24
LT3023106T (lt) 2019-10-25
JP5951634B2 (ja) 2016-07-13
CY1122187T1 (el) 2020-11-25
EP2651436B1 (en) 2016-03-30
HRP20160362T1 (hr) 2016-05-06
HUE045766T2 (hu) 2020-01-28
EP3023106B1 (en) 2019-07-31
SG190937A1 (en) 2013-07-31
MX2013006819A (es) 2013-08-26
US9730992B2 (en) 2017-08-15
SG190731A1 (en) 2013-07-31
CN103260642A (zh) 2013-08-21
PL2651437T3 (pl) 2016-07-29
SI3023106T1 (sl) 2019-11-29
DK2651437T3 (en) 2016-05-02
JP5951633B2 (ja) 2016-07-13
MX344280B (es) 2016-12-09
CA2819297A1 (en) 2012-06-21
PL2651436T3 (pl) 2016-10-31
RS54687B1 (en) 2016-08-31
CN103260642B (zh) 2018-03-16
MX344706B (es) 2017-01-03
KR20130124525A (ko) 2013-11-14
BR112013014599A2 (pt) 2016-09-27
ES2748651T3 (es) 2020-03-17
UA110806C2 (uk) 2016-02-25
US20130280289A1 (en) 2013-10-24
EA027504B1 (ru) 2017-08-31
ES2567190T3 (es) 2016-04-20
EP2651437A1 (en) 2013-10-23
KR20190022897A (ko) 2019-03-06
WO2012080370A1 (en) 2012-06-21
AU2011343368A1 (en) 2013-07-11
EP2651437B1 (en) 2016-02-10
SI2651437T1 (sl) 2016-05-31
EP2651436A1 (en) 2013-10-23
ZA201304014B (en) 2017-04-26
TW201305192A (zh) 2013-02-01
KR101951894B1 (ko) 2019-02-26
SI2651436T1 (sl) 2016-07-29
ES2574403T3 (es) 2016-06-17
AU2011343368B2 (en) 2015-08-20
JP2013545783A (ja) 2013-12-26
HUE028452T2 (en) 2016-12-28
KR20140029376A (ko) 2014-03-10
IL226448A0 (en) 2013-07-31
AU2011343367B2 (en) 2015-05-21
HRP20191843T1 (hr) 2019-12-27
EA027920B1 (ru) 2017-09-29
ZA201304015B (en) 2018-12-19
AU2011343367A1 (en) 2013-07-11
CO6751287A2 (es) 2013-09-16
US20180071378A1 (en) 2018-03-15
IL226450A0 (en) 2013-07-31
US20130287809A1 (en) 2013-10-31
DK2651436T3 (da) 2016-06-20
CN103249431B (zh) 2016-11-02
MY161412A (en) 2017-04-14
CN106822883A (zh) 2017-06-13
JP2014505036A (ja) 2014-02-27

Similar Documents

Publication Publication Date Title
UY33802A (es) Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja
CY1120438T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει μυο-ινοσιτολη και d-κιρο-ινοσιτολη
ECSP11011297A (es) Proteinas ligadoras il-17
AR088513A1 (es) Inmunoenlazantes dirigidos contra esclerostina
CL2013001138A1 (es) Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
CL2014002564A1 (es) Composiciones para tratamiento de agua que comprende un coagulante que contiene aluminio y un polisacarido no derivado natural, en donde la relacion entre el polisacarido y el coagulante es entre 1:10 hasta 1:100; y métodos de uso.
CR20120578A (es) Formulaciones de insulina de acción prolongada
BR112015006426A2 (pt) composições nutricionais que incluem beta-hidróxi-beta-metilbutirato de cálcio, proteína e baixos níveis de eletrólitos
BR112015000520A2 (pt) agente de espessamento estável com lipase
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
EA201290789A1 (ru) Термогелеобразующие композиции анестетиков
EA201190286A1 (ru) Адъювантные композиции, содержащие неионный агент, обеспечивающий изотоничность
TR201909447T4 (tr) Aramkol tuzları.
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
CO6592098A2 (es) Formulacion estable de mia/cd-rap
EA201190285A1 (ru) Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия
AR089269A1 (es) Composiciones para el cuidado oral
BR112015028824A2 (pt) composição de tensoativo concentrada
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
FR2987269B1 (fr) Formulation gelifiante a base de gluconate de calcium
CO7151515A2 (es) Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina
AR093717A1 (es) Composiciones y metodos para el tratamiento de la caries dental
CL2013000771A1 (es) Formulacion acuosa estable que comprende polipeptido del factor estimulante de colonias de granulocitos bovino (bg-csf); liofilizado de la preparacion; proceso para preparar la formulación; uso para tratar infección en un animal.
IT1394921B1 (it) Uso di composti come principi attivi per migliorare l'azione di riparazione cellulare dell'epidermide umana, e composizioni farmaceutiche e cosmetiche che li contengono

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20130805